3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
1278
Carcinoma, Non-Small-Cell Lung
926
Prostatic Neoplasms
729
Neoplasms
633
Multiple Myeloma
554
Lymphoma
540
Colorectal Neoplasms
530
Lung Neoplasms
515
Leukemia
498
Leukemia, Myeloid, Acute
473
Neoplasm Metastasis
471
Melanoma
426
Lymphoma, Non-Hodgkin
420
Ovarian Neoplasms
417
Leukemia, Lymphocytic, Chronic, B-Cell
386
Pancreatic Neoplasms
373
Recurrence
338
Precursor Cell Lymphoblastic Leukemia-Lymphoma
329
Head and Neck Neoplasms
307
Lymphoma, Large B-Cell, Diffuse
295
Glioblastoma
294
Myelodysplastic Syndromes
288
Lymphoma, Follicular
287
Brain Neoplasms
287
Stomach Neoplasms
280
Carcinoma, Renal Cell
268
Carcinoma, Hepatocellular
262
Hodgkin Disease
261
Rectal Neoplasms
256
Sarcoma
250
Interventions
loncastuximab tesirine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Completed
×
Diffuse Large B-Cell Lymphoma Refractory
×
Clear all
NCT03589469
2023-08-29
LOTIS-2
ADC Therapeutics S.A.
Phase 2
Completed
145 enrolled
24 charts
1 FDA